Revolutionizing Algorithm Assessment in Digital Pathology
SPOKANE, Wash., March 22, 2024 /PRNewswire/ -- Gestalt Diagnostics, Inc., a leading provider of (AI)-driven digital pathology solutions, is proud to announce the launch of its leading-edge AI Algorithm Evaluator. This groundbreaking, patent-pending tool empowers pathologists, researchers, and healthcare professionals to assess and compare the performance of AI algorithms with unprecedented precision directly within our award-winning PathFlow® solution. This new feature will be demonstrated during the USCAP 2024 conference in Baltimore this week.
Key Features of PathFlow's AI Algorithm Evaluator:
"With the advancement of AI based Image Analysis in Digital Pathology, PathFlow's AI Algorithm Evaluator offers the modern Pathologist a neutral, unbiased environment to observe, review, score and record performance of algorithms with the goal of identifying the algorithm best suited for the specific clinical/research use-case for their organization," says Roopam Kakoti, VP, Development at Gestalt.
Join us at USCAP, March 23-28, at booth #554 to see how our efforts in clinical, education, and research initiatives are setting new standards in digital solutions.
About Gestalt Diagnostics, Inc.
Gestalt Diagnostics transforms pathology through an intelligent, configurable, vendor-neutral, and AI-driven digital workflow that provides true interoperability enabling pathologists to diagnose* diseases faster and more efficiently. Our PathFlow® solution consists of professional, education, and research modules for ease of mixing and matching the digital needs of your facility in a single solution, freeing pathologists from tedious, repetitive, and manual tasks allowing them to focus on their expertise, providing invaluable experience where it matters most. To learn more, visit www.gestaltdiagnostics.com.
*Research use only unless following CAP guidelines for LDT. CE-IVD certified for use in Europe.
SOURCE Gestalt Diagnostics